We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02049567
Recruitment Status : Completed
First Posted : January 30, 2014
Last Update Posted : May 21, 2021
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of an investigational IOL.

Condition or disease Intervention/treatment Phase
Aphakia Device: FluidVision AIOL Procedure: Cataract Surgery Not Applicable

Detailed Description:
Eligible subjects will receive the investigational IOL in one eye and be followed at 1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months and 36 months post-operation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Clinical Evaluation of the FluidVision Accommodating Intraocular Lens
Actual Study Start Date : January 14, 2014
Actual Primary Completion Date : June 24, 2015
Actual Study Completion Date : November 6, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: FluidVision
FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
Device: FluidVision AIOL
Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Procedure: Cataract Surgery
Performed using standard microsurgical techniques

Primary Outcome Measures :
  1. Accommodative amplitude [ Time Frame: Month 6 ]
    Accommodative amplitude is a measure of the ability of the eye to focus from a target that is at distance into a target that is near.

  2. Best corrected distance visual acuity (BCDVA) [ Time Frame: Month 6 ]
    Visual acuity of the eye will be tested with the correction in place.

  3. Rates of adverse events [ Time Frame: Up to Month 36 ]
    Adverse events will be collected from time of enrollment to study exit

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction;
  • Best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. Brightness Acuity Tester);
  • Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism;
  • Willing and able to comply with schedule for follow-up visits for 36 months after surgery.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes);
  • Taking systemic medications that may confound the outcome or increase the risk to the subject;
  • Ocular conditions that may predispose for future complications;
  • Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject;
  • Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes;
  • Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40.
  • Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02049567

Layout table for location information
PowerVision Investigative Site
Heidelberg, Baden-Württemberg, Germany, D-69120
PowerVision Investigative Site
Stuttgart, Baden-Württemberg, Germany, D-70176
PowerVision Investigative Site
Bochum, North Rhine-Westphalia, Germany, 44892
PowerVision Investigative Site
Berlin, Germany, 10559
South Africa
PowerVision Investigative Site
Claremont, Cape Town, South Africa, 7708
PowerVision Investigative Site
Northcliff, Johannesburg, South Africa, 2195
PowerVision Investigative Site
Queenswood, Pretoria, South Africa, 2001
PowerVision Investigative Site
Paardevlei, Somerset West, South Africa, 7130
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: PowerVision
ClinicalTrials.gov Identifier: NCT02049567    
Other Study ID Numbers: AIOL-2009-1
First Posted: January 30, 2014    Key Record Dates
Last Update Posted: May 21, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by PowerVision:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lens Diseases
Eye Diseases